Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-18
2006-04-18
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S423000, C548S517000, C548S537000
Reexamination Certificate
active
07030151
ABSTRACT:
Atorvastatin calcium, the substance known by the chemical name (R—(R*,R*))-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid hemi calcium salt is known as HMG-CoA reductase inhibitor and is used as an antihypercholesterolemic agent. Atorvastatin in the pharmaceutical compositions available in the market, is usually prepared as its calcium salt since it enables atorvastatin to be conveniently formulated in the pharmaceutical formulations, for example, in tablets, capsules, powders and the like for oral administration. Atorvastatin calcium can exist in an amorphous form or in one of the at least four known crystalline forms (Form I, Form II, Form III and Form IV). Atorvastatin calcium is the substance which is sparingly soluble in water, with pKa 4,5, and it has been found that the crystalline forms are less soluble than the amorphous form, which may cause problems in bioavailability of atorvastatin in the body. The present invention solves the problem of providing therapeutic equivalence of atorvastatin pharmaceutical formulation regardless the form (crystalline, amorphous, mixture of both) of atorvastatin calcium used for its preparation.
REFERENCES:
patent: 5273995 (1993-12-01), Roth
patent: 5686104 (1997-11-01), Mills et al.
patent: 6121461 (2000-09-01), McKenzie
patent: 6531507 (2003-03-01), Pflaum et al.
patent: 6680341 (2004-01-01), Kerc
patent: 6696086 (2004-02-01), Pflaum et al.
patent: 6806290 (2004-10-01), Pflaum et al.
patent: 94/16693 (1994-08-01), None
patent: 97/03958 (1997-02-01), None
patent: 97/03959 (1997-02-01), None
patent: 97/03960 (1997-02-01), None
patent: 00/35424 (2000-06-01), None
patent: 01/76566 (2001-10-01), None
Kearney et al., “The Interconversion Kinetics, Equilibrium, and Solubilities of the Lactone and Hydroxyacid Forms of the HMG-COA Reductase Inhibitor, CI-981”, Pharmaceutical Research, vol. 10, No. 10, pp. 1461-1465 (1993).
Bavec Sa{hacek over (s)}a
Ker{hacek over (c)} Janez
Salobir Mateja
Chung Susannah
Lek Pharmaceuticals d.d.
Saeed Kamal A.
Thallemer John D.
LandOfFree
Atorvastatin calcium in a pharmaceutical form composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Atorvastatin calcium in a pharmaceutical form composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Atorvastatin calcium in a pharmaceutical form composition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3621814